Background: Charcot-Marie-Tooth disease type 1A (CMT1A) accounts for 70 -90% of cases of CMT1 and is most frequently caused by the tandem duplication of a 1.4-Mb genomic fragment on chromosome 17p12. Molecular diagnosis of CMT1A has been based primarily on pulsed-field electrophoresis, fluorescence in situ hybridization, polymorphic allele dosage analysis, and quantitative PCR. We sought to improve the fidelity and applicability of PCR-based diagnosis by developing a panel of novel, highly polymorphic short tandem repeats (STRs) from within the CMT1A duplicated region. Methods: We used a recently available genomic sequence to identify potentially polymorphic simple repeats. We then amplified these sequences in a multiethnic cohort of unaffected individuals and assessed the heterozygosity and number of alleles for each STR.
least 15 loci identified to date (2 ) . Of those, CMT1A is the most common form of the disease, accounting for 70 -90% of CMT1 patients (2 ) . A tandem duplication of a 1.4-Mb genomic fragment on chromosome 17p12 is responsible for most CMT1A cases (3, 4 ) . The CMT1A region is flanked by a set of 24-kb, low-copy number repeats (CMT1A-REPs) (5, 6 ) , and Ͼ99% of the CMT1A duplication is mediated by unequal crossing-over between the proximal and distal CMT1A-REPs [Ref. (2 ) , and references therein]. The gene encoding peripheral myelin protein 22 (PMP22) maps in this interval, and several lines of evidence have indicated that alterations in gene dosage of PMP22 are responsible for the pathogenesis of CMT1A [reviewed in Refs. (7, 8 ) ]. A clinically distinct hereditary neuropathy with liability to pressure palsy (HNPP) has been found allelic to CMT1A, in which deletion of the same 1.4-Mb region is responsible for the disease. Additional molecular studies revealed that CMT1A and HNPP result from a reciprocal interchromosomal recombination event (9 ) .
Several methods have been used in clinical laboratories for the molecular diagnosis of CMT1A and HNPP (10 ) . Conventional Southern hybridization was used initially to visualize the difference in dosage by densitometric measurement using a region-specific probe (3 ) . Subsequently, pulsed-field gel electrophoresis (PFGE) has been used to detect recombination-specific junction fragments (3, 5, 9, 11 ) . More recently, interphase fluorescence in situ hybridization (FISH) analysis was developed for the CMT1A/ HNPP diagnosis, which directly visualizes the gain or loss of the PMP22 signal (12, 13 ) , as well as real-time fluorescent PCR, which measures gene dosage (14 ) . PCR-based methods using short tandem repeats (STRs) (3, 15, 16 ) , quantification of gene dosage (17, 18 ) , and detection of the unique junction fragment of the CMT1A/HNPP recombination (19 ) have also been reported. STR-PCR methods detect three different alleles in CMT1A duplication in combination with semiquantitative dosage measurement. Because of its advantages in cost, amount of DNA sample required, labor, and turnaround time, the STR-PCR method has been widely used for molecular diagnosis of CMT1A. There is, however, a limitation in sensitivity because of the low number of polymorphic markers available in the 1.4-Mb duplicated region. Initially, only one marker, D17S122 (RM11-GT) (3 ) was used for CMT1A PCR-based diagnosis, but its reduced informativeness allowed detection of three alleles in only 46% of CMT1A cases (20 ) . Two studies subsequently identified additional STRs in this region, improving the fidelity of this type of testing to 85% (15, 16 ) . We recently constructed a phage P1 artificial chromosome (PAC) and bacterial artificial chromosome (BAC) contig of the 1.4-Mb CMT1A region and described the complete genome sequence between the CMT1A-REPs (21 ) . In the present study, we used this sequence to identify several STRs that are potentially polymorphic. We hypothesized that new, highly informative STRs may improve our ability to detect genomic rearrangements associated with CMT1A/HNPP, thus enhancing the sensitivity of PCR-based testing and rendering it a more sensitive and informative diagnostic method. Tri-, tetra-, and pentanucleotide repeats could be particularly useful in this process because they typically generate substantially reduced or no stutter peaks. We thus evaluated 34 novel STRs and developed a robust multimarker diagnostic test for CMT1A genomic rearrangements that may be able to detect duplications unambiguously in Ͼ99% of the patients.
Materials and Methods dna samples
To establish the polymorphic potential of newly identified STRs from the CMT1A/HNPP genomic region, we used DNA from 96 unrelated Caucasians collected previously in our laboratory. An additional 36 samples of AfricanAmerican, 36 Asian, and 24 Hispanic individuals were obtained from the Baylor College of Medicine Human Polymorphism Resource. We ascertained the ability to detect genomic rearrangements by genotyping 39 individuals diagnosed with CMT1A. Duplication of the CMT1A region was established independently by densitometric analyses of restriction fragment length polymorphisms from the region, STR analysis with the (CA) n polymorphic marker D17S122 (RM11-GT), detection of a junction fragment with PFGE, or FISH with a PMP22 probe. DNA was extracted either from venous blood or from transformed lymphoblastoid cells by a salting-out process (Puregene; Gentra Systems).
informed consent
We obtained informed consent from all individuals participating in this study in accordance with protocols approved by the Baylor College of Medicine Institutional Review Board.
identification of polymorphic repeats
We analyzed the complete 1.4-Mb genomic sequence of the CMT1A region for STRs with the Sequencher sequence analysis program (GeneCodes Corp.), Repeat Masker (http://repeatmasker.genome.washington.edu/ cgi-bin/RepeatMasker), and the GCG software package (Ver. 9; University of Wisconsin). Fluorescently labeled primers were designed with the Primer Ver. 3 program (www.genome.wi.mit.edu/cgi-bin/primer/primer3.cgi). The 5Ј end of the unlabeled primer was tagged with the sequence GTGTCTT to minimize band stuttering, and primers were obtained from MWG Biotech. All DNA samples were adjusted to 30 ng/L, and PCR reactions were carried out on an MJR Tetrad or a MWG Primus thermocycler with the True Allele PCR premix (PerkinElmer). Amplification conditions were as follows: 95°C for 5 min, followed by 10 cycles of a touchdown sequence, in which the annealing temperature was reduced by 1°C/cycle from 66°C to 56°C, and then 25 cycles at 95°C for 30 s, 56°C for 30 s, and 72°C for 30 s. A final step of 72°C for 5 min was also included. All markers were amplified individually and then pooled according to the panel to which they were binned, with ratios determined by the fluorescent label on each marker [6-carboxy-fluorescein (FAM), 1L; hexachloro-6-carboxyfluorescein (HEX), 2 L; 4,7,2Ј,7Ј-tetrachloro-6-carboxyfluorescein (TET), 2 L]. Products were resolved on an ABI 377 automated sequencer (Applied Biosystems), and alleles were assigned with GENESCAN (Ver. 2.3) and GENO-TYPER (Ver. 2.1) software (Applied Biosystems) as described previously (22 ) .
Results identification of novel STRs from the cmt1a region on 17p12
We identified a total of 42 novel potential polymorphic STRs throughout the 1.4-Mb CMT1A/HNPP genomic interval. Subsequent alignments using unique sequence flanking each repeat confirmed that these STRs did not overlap with any existing genetic markers. We did, howClinical Chemistry 47, No. 5, 2001 ever, eliminate eight STRs from further analyses because these were embedded in Alu-and LINE1-rich regions, which precluded the design of suitable amplification primers.
str evaluation and characterization
We selected 34 STRs, including 20 di-, 1 tri-, 10 tetra-, and 3 pentanucleotide repeats. We first ascertained the polymorphic potential of all markers on a panel of eight R-GTGTCTT GCT TTC ATT CTG AGC ATT GG  D17S2219  F-ATA AAA GAT GAG TTG CTT GG  224-260  16  TET  1  Di  R-GTGTCTT AAT CGT TCA TGT TGT GGA TG  D17S2225  F-TGT ATC TGG GAG TAT TCA CG  245-263  10  FAM  1  Di  R-GTGTCTT GCA CCT TTA TGG GGA GTT AG  D17S2226  F-GCA TTC TTG TCT CAG TCC TG  112-148  10  TET  1  Tetra  R-GTGTCTT CCA GAG CTA ACA CCA CAT TC  D17S2220  F-CCT CAG TCA TCT TTC TCC TT  284-340  15  FAM  1  Tetra  R-GTGTCTT TGG GCA ACA GAG CAA AAT CC  D17S2221  F-GAA AAT TTC CCA AAA GG  112-148  10  FAM  1  Di  R-GTGTCTT CCT CTC CCT GAG TGT CTG GT  D17S2224  F-GTGTCTT GTT CAT TCT ATC GTC TCA AA  179-207  8  TET  1  Tetra  R-AAG GCT ACC ATA AAT CTT GT  D17S2229  F-CCC ATT CCA TAG TCA TCA GA  243-269  13  HEX  1  Di  R-GTGTCTT TGC CAT TTT ACC ACA AGA GG  D17S2216  F-AGG CAC GGG ATT AGG AAG TT  186-214  13  HEX  1  Di  R-GTGTCTT GCA GTT TGG AAG GCT GGA GA  D17S2227  F-TTA AAC TAG CAT TCT TCC AA  234-284  10  FAM  2  Penta  R-GTGTCTT TAA CCA GTT TCA TCT CAC AG  D17S2228  F-GGC TGT CAT AAA TGT TCC TA  164-182  7  HEX  2  Tri  R-GTGTCTT AGG TAA AGG TTC TGG TGA GC  D17S2223  F-TAC AAG AAA GGG AAC AAA GC  151-179  15  FAM  2  Di  R-GTGTCTT TGA AGA AGC AAG AGA CGA GT  D17S2222  F-CCC TGA GTC TCT TAC TTT CT  185-211  11  FAM  2  Di  R-GTGTCTT TGA GAT GGA TAG AGC TAT GG  D17S2230  F-GGA AAC TGA TGT CTA AAA CT  217-282  13  TET  2 Penta R-GTGTCTT GTG AAT CCA GGA GGC AGA GC a Markers have been numbered consecutively ptel-cen and divided into two panels; markers in each panel can be resolved concurrently. b F, forward; R, reverse. c Di, dinucleotide; tri, trinucleotide; tetra, tetranucleotide; and penta, pentanucleotide repeats.
control DNA samples. STRs were evaluated for the following criteria: (a) heterozygosity Ն65%; (b) identification of more than four alleles; (c) allele-peak uniformity; and (d) minimal interference by shadow alleles.
At the conclusion of this analysis, we selected 15 STRs from across the CMT1A region that best fit the above criteria ( Fig. 1 and Table 1 ) and evaluated them further by genotyping in 96 unrelated Caucasian control DNAs. We identified Ͼ10 alleles in 13 of 15 markers; 1 marker had 7 alleles (Table 1 ; D17S2228), whereas some markers had as many as 16 alleles (Table 1; D17S2219) . The heterozygosity values obtained were likewise suggestive of high informativeness because they were 59 -93% (Table 2 ). To ascertain the potential global applicability of these markers, we also assessed the same criteria in a cohort of African-American, Asian, and Hispanic individuals. In most cases, we found no significant variation in allele frequencies among the different ethnicities (Table 2) . However, in a few cases, including D17S2222, D17S2228, and D17S2230, such differences were evident, suggesting that the ethnicity of the patient may become relevant to the diagnostic applicability of some STRs.
identification of duplications in patients with cmt1a
Given the above data, we hypothesized that this panel of 15 markers would detect duplications accurately in the patients with CMT1A. To test this hypothesis, we genotyped 39 unrelated individuals who had previously been diagnosed with CMT1A duplication by multiple criteria, including densitometry of restriction fragment length polymorphism bands, detection of junction fragments with PFGE, and identification of three alleles with microsatellite RM11-GT, and/or FISH. No individual marker detected three alleles in every patient. However, the combination of all markers identified duplications (i.e., three alleles) in 39 of 39 samples (Table 3) . Furthermore, there were only 2 cases in which the duplication was detected by a single marker; genomic rearrangements in the remaining 37 patients were clearly visible by a minimum of 3 and a maximum of 11 STRs (Fig. 2) .
Discussion
Recent advances in the Human Genome Project will not only impact the identification of disease genes and further our understanding of basic cellular processes, but are also likely to substantially improve our ability to diagnose genetic disorders accurately, inexpensively, and expeditiously. In this work, we used sequence information from the CMT1A/HNPP genomic region (21 ) to identify and characterize novel microsatellites. We also demonstrated that the combinatorial use of a panel of 15 of these markers was able to detect duplications in all 39 CMT patients who had been diagnosed previously to harbor such a duplication. It is therefore possible to apply this marker set for CMT1A diagnostic testing. Until now, CMT1A diagnosis has relied heavily on densitometric analyses of restriction fragment length polymorphisms, PFGE data, FISH, and quantitative determination of dosage, primarily because of the reduced availability of polymorphic markers spanning the CMT1A genomic region. Initial STR-based studies identified only 46% of duplications (20 ) , which was later improved to 80 -90% (12, 13 ) . Despite these improvements, a substantial fraction of CMT1A duplication cases remained undetectable, necessitating the application of more time-consuming and expensive techniques. The new STR panel presented here will substantially improve the feasibility of the PCR-based diagnosis of CMT1A/HNPP because it can potentially detect Ͼ99% of duplication cases. Furthermore, the allelesize ranges of this new marker set were selected to allow the construction of two panels of markers that are ame- D17S2218  87  78  77  69  D17S2227  82  78  71  79  D17S2217  68  67  74  75  D17S2219  67  86  83  58  D17S2225  63  89  89  71  D17S2226  71  91  75  79  D17S2228  67  44  46  63  D17S2220  88  75  89  83  D17S2221  73  86  51  79  D17S2223  71  75  81  71  D17S2224  71  89  86  67  D17S2222  59  81  56  79  D17S2229  93  86  81  71  D17S2216  85  ---D17S2230 69 89 38 50 nable to multiplexing. Panel 1 alone, consisting of 10 markers, was sufficient to identify 37 of 39 duplications in our cohort. We therefore recommend that panel 2 needs to be used only in the absence of three alleles from any panel 1 marker. This will allow high-throughput analysis and is likely to reduce the cost of testing.
PCR-based data of HNPP deletions are typically less robust because they do not allow direct detection of the deletion, but only infer the deletion by detecting a single allele for any marker tested. The availability of a large set of highly informative markers will improve the ability to diagnose deletions because the probability that 15 highly polymorphic loci will be homozygous, rather than hemizygous in any given patient sample, is small.
Our data are also relevant to understanding the mechanism by which the duplication (CMT1A) and deletion (HNPP) are generated. Such genomic rearrangements are the result of unequal crossing-over between a set of low copy repeats flanking the 1.4-Mb CMT1A region. The finding of three alleles in all duplicated patients indicates that homologous recombination between chromosomes (interchromosomal homologous recombination) is the more common cause of this rearrangement, rather than intrachromosomal homologous recombination (23 ) . The latter would give rise to two copies of the allele, a phenomenon detectable only through calculation of the ratios of the surface area of each allele peak. Because this is less accurately detectable, the presence of rare cases of intrachromosomal recombination in de novo duplication patients is a potential error in informative, polymorphicallele PCR-based approaches and should be considered when a third allele is not seen with any marker. In such cases, PFGE or FISH would be the recommended method of choice for fully informative analysis, but quantification of peak heights for multiple heterozygous STR alleles may suffice.
